4SC-203

WARNING: This product is for research use only, not for human or veterinary use.

Description:4SC-203 is a multikinase inhibitor with potential antineoplastic activity. Multikinase inhibitor 4SC-203 selectively inhibits FMS-related tyrosine kinase 3 (FLT3/STK1), FLT3 mutated forms, and vascular endothelial growth factor receptors (VEGFRs). This may result in the inhibition of angiogenesis and cell proliferation in tumor cells in which these kinases are upregulated. FLT3 (FLK2), a class III tyrosine kinase receptor, is overexpressed or mutated in most B lineage and acute myeloid leukemias (AML). VEGFRs, tyrosine kinase receptors, are overexpressed in a variety of tumor cell types and play key roles in angiogenesis.

Price and Availability

4SC-203, purity > 98%, is not in stock, may be available through custom synthesis. Minimum 1 gram order is requested. Current shipping out time is about 70 days after order is received.

Chemical Structure

Theoretical Analysis

MedKoo Cat#: 205802Name: 4SC-203CAS#: 895533-09-2Chemical Formula: C33H38N8O4SExact Mass: 642.27367Molecular Weight: 642.77Elemental Analysis: C, 61.66; H, 5.96; N, 17.43; O, 9.96; S, 4.99

Synonym:4SC203; 4SC-203; 4SC 203; SC71710; SC-71710; SC 71710.

IUPAC/Chemical Name:1-(2-methoxy-5-methylphenyl)-3-(6-((6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinazolin-4-yl)amino)benzo[d]thiazol-2-yl)urea

InChi Key:MAFACRSJGNJHCF-UHFFFAOYSA-N

InChi Code:InChI=1S/C33H38N8O4S/c1-21-6-9-27(43-3)26(16-21)37-32(42)39-33-38-24-8-7-22(17-30(24)46-33)36-31-23-18-28(44-4)29(19-25(23)34-20-35-31)45-15-5-10-41-13-11-40(2)12-14-41/h6-9,16-20H,5,10-15H2,1-4H3,(H,34,35,36)(H2,37,38,39,42)

SMILES Code:O=C(NC1=NC2=CC=C(NC3=C4C=C(OC)C(OCCCN5CCN(C)CC5)=CC4=NC=N3)C=C2S1)NC6=CC(C)=CC=C6OC

Technical Data

Additional Information

4SC-203 is a novel multi-target kinase inhibitor. In preclinical testing the compound has shown unique and strong selectivity against a set of kinases including FLT3, FLT3 mutants and VEGF-receptors. FLT3 is involved in the growth and maturation of normal blood cells. With the inhibition of VEGF receptor tyrosine kinases, 4SC-203 may also inhibit angiogenic processes – i.e. the formation of vascular structures that provide nutrition for tumours enabling them to grow rapidly – and could therefore also be applicable in solid cancer types. 4SC-203 was jointly developed with ProQinase GmbH, a company based in Freiburg, Germany. The molecule has successfully completed a randomised, double-blind, placebocontrolled Phase I study in healthy volunteers which demonstrated the safety, tolerability and pharmacokinetics of this intravenously delivered compound. (source: http://www.4sc.de/product-pipeline/clinical/4SC-203).      

References